A report released by a UK parliamentary committee has called for a significant increase in the availability of weight-loss injections, such as Mounjaro, within the National Health Service (NHS). The committee expressed concern that the government's existing strategy, which aims to provide the medication to approximately 6% of eligible patients by 2028, is far too limited given the high prevalence of obesity in the country.

MPs argue that expanding access to these treatments could provide substantial health benefits and reduce the long-term burden on the healthcare system. The committee’s recommendations suggest that the current rollout pace does not match the urgency of the public health challenge. While the government has previously signaled support for integrating these drugs into weight management programs, the committee’s findings highlight a clear disagreement regarding the speed and scale of implementation. The MPs suggest that a more ambitious target is necessary to effectively combat obesity-related health issues, though they acknowledge that logistical and supply chain constraints remain a factor in the drug's distribution.